SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+3.53%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$546M
AUM Growth
+$546M
(+3.9%)
Cap. Flow
+$4.98M
Cap. Flow
% of AUM
0.91%
Top 10 Holdings %
Top 10 Hldgs %
55.37%
Holding
35
New
6
Increased
12
Reduced
15
Closed
2
Top Buys
| 1 |
Pfizer
PFE
|
$28M |
| 2 |
Baxter International
BAX
|
$17.5M |
| 3 |
Centene
CNC
|
$9.87M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$6.93M |
| 5 |
Ionis Pharmaceuticals
IONS
|
$5.99M |
Top Sells
| 1 |
Abbott
ABT
|
$16.7M |
| 2 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$14.9M |
| 3 |
Boston Scientific
BSX
|
$11.9M |
| 4 |
Gilead Sciences
GILD
|
$10.3M |
| 5 |
Labcorp
LH
|
$6.71M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pfizer
PFE
$141B
| $49.5M | 9.06% | 1,365,763 +772,513 | +130% | +$28M |
|
|
2
Gilead Sciences
GILD
$140B
| $43.9M | 8.03% | 678,633 -159,507 | -19% | -$10.3M |
|
3
Merck
MRK
$210B
| $39M | 7.15% | 506,176 -72,035 | -12% | -$5.55M |
|
4
Incyte
INCY
$16.5B
| $27.7M | 5.08% | 341,051 -10,578 | -3% | -$860K |
|
5
Medtronic
MDT
$119B
| $27.1M | 4.96% | 229,323 -8,200 | -3% | -$969K |
|
6
Becton Dickinson
BDX
$55.3B
| $24.8M | 4.53% | 101,787 -20,058 | -16% | -$4.88M |
|
7
Bruker
BRKR
$5.16B
| $24.3M | 4.45% | 377,767 +50,290 | +15% | +$3.23M |
|
8
Bristol-Myers Squibb
BMY
$96B
| $23.4M | 4.29% | 371,062 +9,719 | +3% | +$614K |
|
|
9
Centene
CNC
$14.3B
| $22.3M | 4.08% | 348,451 +154,439 | +80% | +$9.87M |
|
|
10
Ionis Pharmaceuticals
IONS
$6.79B
| $20.4M | 3.74% | 454,150 +133,158 | +41% | +$5.99M |
|
11
Elevance Health
ELV
$71.8B
| $20.4M | 3.73% | 56,771 +9,411 | +20% | +$3.38M |
|
12
Cardinal Health
CAH
$35.5B
| $19.7M | 3.61% | 324,464 +33,614 | +12% | +$2.04M |
|
|
NUVA
13
DELISTED
NuVasive, Inc.
NUVA
| $18.3M | 3.35% | 279,259 +23,899 | +9% | +$1.57M |
|
14
CVS Health
CVS
$92.8B
| $18M | 3.3% | 239,463 +3,645 | +2% | +$274K |
|
|
15
Baxter International
BAX
$12.7B
| $17.5M | 3.2% | +206,951 | New | +$17.5M |
|
16
Revvity
RVTY
$10.5B
| $15.1M | 2.76% | 117,467 -26,464 | -18% | -$3.4M |
|
|
17
Boston Scientific
BSX
$156B
| $14.7M | 2.7% | 381,536 -308,746 | -45% | -$11.9M |
|
18
Biogen
BIIB
$19.4B
| $13.8M | 2.52% | 49,260 -16,325 | -25% | -$4.57M |
|
19
Elanco Animal Health
ELAN
$9.12B
| $12.4M | 2.27% | 419,979 +51,688 | +14% | +$1.52M |
|
|
20
Labcorp
LH
$23.1B
| $11.7M | 2.14% | 45,741 -26,323 | -37% | -$6.71M |
|
21
Bio-Rad Laboratories Class A
BIO
$8.06B
| $11.2M | 2.05% | 19,557 -1,860 | -9% | -$1.06M |
|
22
LivaNova
LIVN
$3.08B
| $10.4M | 1.91% | 141,483 -59,747 | -30% | -$4.41M |
|
23
Alnylam Pharmaceuticals
ALNY
$58.5B
| $8.44M | 1.55% | 59,789 +30,174 | +102% | +$4.26M |
|
24
Perrigo
PRGO
$3.27B
| $8.29M | 1.52% | 204,878 +36,956 | +22% | +$1.5M |
|
|
ALXN
25
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $7.75M | 1.42% | 50,657 -97,170 | -66% | -$14.9M |
|